Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy of Lapaquistat Acetate Alone or Coadministered With Atorvastatin in Subjects With Primary Dyslipidemia

NCT00487994 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00487994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00487994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy of Lapaquistat Acetate Alone or Coadministered With Atorvastatin in Subjects With Primary Dyslipidemia
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2004
Completion date
May 31, 2007
Enrollment
2,130 (actual)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia